Moderate to Severe Atopic Dermatitis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Moderate to Severe Atopic Dermatitis Emerging Therapy and TPP Insights

Thelansis’s “Moderate to Severe Atopic Dermatitis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Moderate to Severe Atopic Dermatitis Overview

Moderate to severe atopic dermatitis is a chronic, relapsing inflammatory skin condition marked by intense itch and skin barrier dysfunction that meaningfully affects daily functioning and often requires systemic rather than purely topical treatment. The field has moved decisively into a targeted therapy era, with biologic antibodies directed at specific interleukin pathways, alongside oral JAK inhibitors offering a convenient once-daily pill alternative, largely displacing older broad immunosuppressants as go-to systemic options. With several agents now approved, each offering a somewhat different balance of efficacy, dosing convenience, and safety considerations, the central challenge for prescribers has shifted from a lack of options to selecting the right therapy for an individual patient, a decision further shaped by age, pregnancy status, and prior treatment history. Newer non-steroidal topical options have also expanded choices for milder disease. The pipeline continues to diversify beyond the pathways that defined the last decade, with newer agents aiming to differentiate through simplified dosing in an increasingly crowded field.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)